Mitochon Pharmaceuticals

Mitochon Pharmaceuticals is a clinical stage biotech company that develops drugs that are neuroprotective and prevent neurodegenerative disease progression.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Philadelphia, PA, US
  • Currency USD
  • Founded November 2014
  • Employees 2
  • Incorporation Type S-corp
  • Website mitochonpharma.com

Company Summary

Mitochon Pharmaceuticals is a clinical stage biotech company in Phase I/II testing. The company is focused on developing disease modifying drugs that target the mitochondria and attenuate neurodegeneration, with a focus on: Huntington’s, ALS, Progressive MS, and Traumatic Brain Injury. Our programs have been shown to protect cells by modulating the mitochondria to reduce oxidative stress, while promoting mitochondrial biogenesis.

Team

  • Robert Alonso

  • John Geisler
    Chief Scientific Officer

    John is an experienced pharmacologist with a research background on mitochondria and energetics. John has worked at ISIS, Pfizer and JNJ with a focus on metabolic functioning of cells and testing drugs on their metabolic activity

  • Marcus Keep
    Chief Medical Officer

    Marcus Keep, Acting CMO, MD-Board Certified Neurosurgeon in Canada and the USA, active as neuro-trauma neurosurgeon at level 1 trauma center. Co-founder and Board member for 18 years of Swedish publicly traded neuroprotection and primary mitochondria disease company, Abliva AB. Research in ALS and neuroprotection.

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free